Lupus Anticoagulant and Cardiopulmonary Bypass

Semin Thromb Hemost 2022; 48(05): 628-630
DOI: 10.1055/s-0042-1750045

Letter to the Editor

Deepa J. Arachchillage

¹Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, United Kingdom

²Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

³Department of Haematology, Royal Brompton Hospital, London, United Kingdom

,

Christina Crossette-Thambiah

¹Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, United Kingdom

²Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

,

Mike Laffan

¹Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, United Kingdom

²Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

References
1 Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017; 178 (02) 181-195
2 Culliford AT, Gitel SN, Starr N. et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981; 193 (01) 105-111
3 Ranger A, Gaspar M, Elkhatteb A. et al. The heparin-von Willebrand factor interaction and conventional tests of haemostasis - the challenges in predicting bleeding in cardiopulmonary bypass. Br J Haematol 2021; 192 (06) 1073-1081
4 Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20 (03) 231-236
5 Massoudy P, Cetin SM, Thielmann M. et al. Antiphospholipid syndrome in cardiac surgery-an underestimated coagulation disorder?. Eur J Cardiothorac Surg 2005; 28 (01) 133-137
6 Ciocca RG, Choi J, Graham AM. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg 1995; 170 (02) 198-200